We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
HARUROPI (Accelagen Pty Ltd)
Product name
HARUROPI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
Ropinirole hydrochloride
Registration type
EOI
Indication
HARUROPI® is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic Parkinson's disease from early stage to advanced disease.